Microbiota-Associated Metabolites as Biomarkers and Therapeutic Opportunities in Inflammatory Bowel Disease
Nutrients · 2026
DOI: 10.3390/nu18203372 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, 2026. Verfasst von Krystian Krysa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health Sciences and Psychology, Collegium Medicum, University of Rzeszow, Warzywna 1a, 35-959 Rzeszow, Poland. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Gastrointestinal Microbiome. Die Arbeit nennt 186 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, are chronic inflammatory conditions of the gastrointestinal tract characterized by periods of active disease and remission. Their pathogenesis is multifactorial and involves genetic predisposition, immune response, environmental factors, and alterations in gut microbiota composition and function. Growing evidence suggests that gut microbiota-associated metabolites not only reflect disease activity but also participate in regulating the immune response and maintaining the integrity of the intestinal barrier. The most important groups of metabolites associated with inflammatory bowel diseases include short-chain fatty acids, bile acids, and tryptophan derivatives. Reduced fecal butyrate and acetate concentrations have been reported in inflammatory bowel diseases, although the diagnostic value of fecal short-chain fatty acids remains uncertain. Potential therapeutic approaches include short-chain fatty acid supplementation, particularly sodium butyrate, and dietary interventions aimed at increasing short-chain fatty acid concentrations; however, the clinical efficacy of short-chain fatty acid supplementation remains inconclusive, and evidence for dietary interventions is limited. In the future, the use of gut microbiota metabolites may be based on personalized strategies grounded in multiomic data, enabling precise modulation of the microbiota–metabolite–immune system axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Health Sciences and Psychology, Collegium Medicum, University of Rzeszow, Warzywna 1a, 35-959 Rzeszow, Poland.
- University Center for Research and Development in Health Sciences, University of Rzeszow, Warzywna 1a, 35-959 Rzeszow, Poland.
- Student Scientific Club of Human Nutrition, Faculty of Health Sciences and Psychology, Collegium Medicum, University of Rzeszow, Warzywna 1a, 35-959 Rzeszow, Poland.
ORCID-Profile: Krystian Krysa, Patrycja Musz, Paulina Serafin, Sara Jarmakiewicz-Czaja
Zitieren
APA
Krysa, K., Musz, P., Ryś, G., Serafin, P., Wachowiak, D., & Jarmakiewicz-Czaja, S. (2026). Microbiota-Associated Metabolites as Biomarkers and Therapeutic Opportunities in Inflammatory Bowel Disease. Nutrients. https://doi.org/10.3390/nu18203372
Vancouver
Krysa K, Musz P, Ryś G, Serafin P, Wachowiak D, Jarmakiewicz-Czaja S. Microbiota-Associated Metabolites as Biomarkers and Therapeutic Opportunities in Inflammatory Bowel Disease. Nutrients. 2026. doi:10.3390/nu18203372
BibTeX
@article{Krysa2026,
author = {Krysa, Krystian and Musz, Patrycja and Ryś, Gabriela and Serafin, Paulina and Wachowiak, Dawid and Jarmakiewicz-Czaja, Sara},
title = {Microbiota-Associated Metabolites as Biomarkers and Therapeutic Opportunities in Inflammatory Bowel Disease},
journal = {Nutrients},
year = {2026},
doi = {10.3390/nu18203372}
}
EUVIMED